Targeting SMOX for the treatment of hepatocellular carcinoma? - 08/08/24
Doi : 10.1016/j.clinre.2024.102429
Yulei Tao, Chunming Cheng ⁎ 
Department of Oncology Science, OU Health Stephenson Cancer Center at University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
⁎Corresponding author.
Summary |
Dysregulation of the polyamine metabolism is common in different cancer types. SMOX is upregulated in hepatocellular carcinoma (HCC) but the relationship between SMOX and liver inflammation and fibrosis, remains unclear. In this issue of Clin Res Hepatol Gastroenterol, Hu and colleagues find targeting SMOX can alleviate liver cancer progression.
Le texte complet de cet article est disponible en PDF.Keywords : Polyamine metabolism, Hepatocellular carcinoma, HCC, SMOX, Liver inflammation, Fibrosis, Treatment
Plan
© 2024
Publié par Elsevier Masson SAS.
Vol 48 - N° 8
Article 102429- octobre 2024 Retour au numéro
Article précédent
- Giant cell hepatitis associated with autoimmune hemolytic anemia: More evidence for B-cell depletion therapy for a rare immune mediated disease of infancy
- Giuseppe Maggiore, Marco Sciveres
- Reply to comments on “Dependent functional status is an independent risk factor for 30-day mortality and morbidities following colectomy for volvulus: An ACS- NSQIP study from the United States”
- Renxi Li
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?